Dried blood spot analysis of donepezil in support of a GLP 3-month dose-range finding study in rats.
Donepezil hydrochloride is a reversible acetyl cholinesterase inhibitor approved for Alzheimer disease treatment. As an alternate therapy, a donepezil hydrochloride transdermal patch is in development. Recommended nonclinical safety studies include a 3-month Good Laboratory Practice (GLP) dose-range finding (DRF) study prior to conducting the 2-year dermal carcinogenicity study in rats. Demonstration of systemic exposure is necessary to interpret the in vivo data. Previous nonclinical reports supporting oral dosing have utilized liquid chromatography tandem mass spectrometry (LC/MS/MS) to quantify donepezil concentrations in plasma. Smaller species with limited blood volumes do not allow serial sampling to derive the full pharmacokinetic profile from a single animal. Therefore, the option of another analytical method requiring decreased sample volumes is desirable as it would decrease the required number of animals while obtaining the complete profile. The dried blood spot (DBS) technique allows drug level measurement from a few microliters; however, the method is still not widely utilized in GLP studies. Because donepezil plasma levels are known by the oral route, DBS was used to bridge the previous oral data and to support a 13-week GLP DRF study for repeated topical application in rats, comparing oral administration with 4 topical formulations. The DBS method was validated and demonstrated robustness and reproducibility for application to the DRF study. The assay results were comparable to a previously reported plasma LC/MS/MS assay-derived pharmacokinetic profile and provided justification for selection of the topical formulation and dose levels for the subsequent dermal carcinogenicity study.
Teikoku Pharma USA Inc, San Jose, CA, USA. smeierdavis@teikokuusa.com
Susan R
SR
Meier-Davis
Min
M
Meng
Weiwei
W
Yuan
Lisa
L
Diehl
Fatima M
FM
Arjmand
Rebecca M
RM
Lucke
Betsy
B
Huang
Jianye
J
Wen
Jutaro
J
Shudo
Tetsuto
T
Nagata
D000284:Administration, Oral; D000287:Administration, Topical; D000818:Animals; D002800:Cholinesterase Inhibitors / Q000494:pharmacology*; D002853:Chromatography, Liquid / Q000379:methods; D000077265:Donepezil; D004305:Dose-Response Relationship, Drug; D059788:Dried Blood Spot Testing / Q000379:methods*; D005260:Female; D007189:Indans / Q000494:pharmacology*; D007753:Laboratories / Q000331:legislation & jurisprudence*; D008297:Male; D010880:Piperidines / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D015203:Reproducibility of Results; D053719:Tandem Mass Spectrometry / Q000379:methods; D018675:Toxicity Tests
D002800:Cholinesterase Inhibitors; D007189:Indans; D010880:Piperidines; D000077265:Donepezil